Skip to main content

Author: Jennifer Shen


Introducing the subcutaneous depot medroxyprogesterone acetate injectable contraceptive via social marketing: lessons learned from Nigeria’s private sector

The subcutaneous depot medroxyprogesterone acetate (DMPA-SC) injectable contraceptive was introduced in South West Nigeria in 2015 through private sector channels. The introduction included community-based distribution and was supported by a social marketing approach. From program monitoring and evaluation, aimed at understanding performance, market reach and other process measures, we identify lessons learned to inform future scale-up efforts. We synthesized the findings from a core set of key performance indicators collected through different methods: (1) implementer performance indicators, (2) phone survey of DMPA-SC users (n=541) with a follow-up after 3 months (n=342) and (3) in-depth interviews with 57 providers and 42 users of DMPA-SC

Institutional author(s): University of California San Francisco, Akena Associates, DKT Nigeria, American University of Beirut
Individual author(s): Jenny Liu, Eric Schatzkin, Elizabeth Omoluabi, Morenike Fajemisin, Chidinma Onuoha, Temitope Erinfolami, Kazeem Ayodeji, Saliu Ogunmola, Jennifer Shen, Nadia Diamond-Smith, Maia Sieverding
Publication date: July, 2018

Journal article Link to Journal Article

Predictors of DMPA-SC continuation among urban Nigerian women: the influence of counseling quality and side effects

In 2015, private healthcare providers in Nigeria introduced DMPA-SC (depot medroxyprogesterone acetate administered subcutaneously) into the method mix. We aimed to [1] examine the sociodemographic predictors of continued DMPA-SC use after 3 months, and [2] characterize the additional influences of contraceptive counseling quality and experiences of side effects on continuation. From March to August, 2016, we conducted phone interviews with a convenience sample of women obtaining DMPA-SC from selected providers to survey them about their experience obtaining an initial dose of DMPA-SC. Study coordinators contacted women again about 3 months later after when they were due for reinjection. We used logistic regressions to examine the likelihood of having obtained a subsequent dose of DMPA-SC at follow-up as predicted by sociodemographic characteristics, a quality of counseling indicator based on responses to a 14-item scale, and reports of side effects experienced.

Institutional author(s): University of California San Francisco
Individual author(s): Jenny Liu, Jennifer Shen, Nadia Diamond-Smith
Publication date: May, 2018

Journal article Link to Journal Article